RxDoctor Payments Data

Anna Korkis, MD

Gastroenterology · Ridgewood, NJNPI 1912014887

Payments from drug & device makers

$4,926in general payments, 2019–2025

Across 269 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$652
  • E.r. Squibb & Sons, L.L.C.$567
  • Bristol Myers Squibb$463
  • Takeda Pharmaceuticals U.S.A., Inc.$395
  • AbbVie$347
  • Pfizer$295
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,903100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,926 in reported general payments places this provider in the 65th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$282,402
Medicare patients
261
Services billed
2,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$23,827
NexiumEsomeprazole Magnesium11$8,211
Mesalamine11$5,798
Sucralfate60$5,513
Omeprazole353$5,203
Esomeprazole Magnesium87$5,152
Balsalazide Disodium12$2,861
Ezetimibe-SimvastatinEzetimibe/Simvastatin26$2,356
Omega-3 Acid Ethyl Esters16$1,690
SynthroidLevothyroxine Sodium16$1,229
Famotidine51$1,228
Losartan Potassium80$1,033
Olmesartan Medoxomil31$1,002
Levothyroxine Sodium69$977
Pantoprazole Sodium41$869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$38$23,82713 claims
AbbVieSynthroid$347$1,22916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Ridgewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →